BVAC-E6E7
Phase 1A therapeutic vaccine for HPV16- or HPV18-positive head and neck squamous cell carcinoma, in a Phase 1/2a trial at Seoul National University Hospital and Severance, supported by the Korea Drug Development Fund.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has dosed the first patient in a Phase 1/2a trial of its head and neck cancer vaccine BVAC-E6E7 with in-house drug product.
Roles often seen at this stageClinical & PV · Manufacturing & MSAT · Research & development
A biotech company developing therapeutic cancer vaccines and preventive vaccines, producing clinical drug product at its own GMP facility.
A therapeutic vaccine for HPV16- or HPV18-positive head and neck squamous cell carcinoma, in a Phase 1/2a trial at Seoul National University Hospital and Severance, supported by the Korea Drug Development Fund.
A therapeutic vaccine candidate for cervical cancer.
Dosed the first patient in the BVAC-E6E7 Phase 1/2a trial with drug product made at its own GMP facility.
Selected for a 2026 Korea Drug Development Fund lead-compound research project.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.